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Abstract
The neovascular (wet) form of age-related macular degeneration (AMD) leads to vision loss due to choroidal
neovascularization (CNV). Since macrophages are important in CNV development, and cytomegalovirus (CMV)-specific
IgG serum titers in patients with wet AMD are elevated, we hypothesized that chronic CMV infection contributes to wet
AMD, possibly by pro-angiogenic macrophage activation. This hypothesis was tested using an established mouse model of
experimental CNV. At 6 days, 6 weeks, or 12 weeks after infection with murine CMV (MCMV), laser-induced CNV was
performed, and CNV severity was determined 4 weeks later by analysis of choroidal flatmounts. Although all MCMV-infected
mice exhibited more severe CNV when compared with control mice, the most severe CNV developed in mice with chronic
infection, a time when MCMV-specific gene sequences could not be detected within choroidal tissues. Splenic macrophages
collected from mice with chronic MCMV infection, however, expressed significantly greater levels of TNF-a, COX-2, MMP-9,
and, most significantly, VEGF transcripts by quantitative RT-PCR assay when compared to splenic macrophages from control
mice. Direct MCMV infection of monolayers of IC-21 mouse macrophages confirmed significant stimulation of VEGF mRNA
and VEGF protein as determined by quantitative RT-PCR assay, ELISA, and immunostaining. Stimulation of VEGF production
in vivo and in vitro was sensitive to the antiviral ganciclovir. These studies suggest that chronic CMV infection may serve as a
heretofore unrecognized risk factor in the pathogenesis of wet AMD. One mechanism by which chronic CMV infection
might promote increased CNV severity is via stimulation of macrophages to make pro-angiogenic factors (VEGF), an
outcome that requires active virus replication.
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Introduction
Angiogenesis, the formation of blood vessels, plays a critical role
in embryonic development, wound healing, and normal physio-
logic processes associated with natural growth and development.
On the other hand, new blood vessel growth (neovascularization)
contributes to a number of pathologic conditions that include
atherosclerosis and tumor formation [1,2]. The eye is also
particularly sensitive to neovascularization during which abnormal
blood vessel growth within retinal or choroidal tissues leads to
vision loss or blindness. Sight-threatening diseases of the eye
associated with abnormal neovascularization include diabetic
retinopathy [3], retinopathy of prematurity [4], and age-related
macular degeneration (AMD) [5].
Of these, AMD is the leading cause of severe irreversible central
vision loss and legal blindness in individuals 65 years of age or
older in the United States and other developed countries [6–9].
Since the number of elderly persons will double by 2020, AMD is
expected to become a major public health problem. Two forms of
AMD are recognized [5–10]. The non-neovascular form (also
known as ‘‘dry’’ or ‘‘nonexudative’’) represents an early form of
AMD usually associated with little visual acuity loss. It is
characterized by atrophic abnormalities of the retinal pigment
epithelium (RPE) and drusen, small lesions at the level of the RPE
that contain granular and vesicular lipid-rich material. Over time,
however, this form of AMD often progresses to the neovascular
(also known as ‘‘wet’’ or ‘‘exudative’’) form of AMD that results in
significant vision loss due to the appearance of choroidal
neovascularization (CNV). Although the precise events that
contribute to the development of AMD remain uncertain, recent
studies have implicated various immunological and inflammatory
mechanisms. For example, complement deposition has been
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publications have demonstrated that polymorphisms in comple-
ment factor-H are associated with an increased risk of AMD [11–
14]. Several investigators have also identified macrophages in
association with drusen as well as choroidal neovascular
membranes [15–18] suggesting a role for macrophages in the
pathophysiology of both forms of AMD. In support of this
hypothesis, we [19], and others [20], have shown in a mouse
model of experimental CNV that depletion of macrophages
significantly decreases the size and severity of lesions.
Macrophages are immune cells of monocyte origin that are
classically associated with innate immune responses, particularly
inflammation [21], but they may also exhibit pro-angiogenic as
well as anti-angiogenic activities [22]. Thus, macrophages may
exist in different activation states [23], and individuals may
therefore vary in activation states as defined by expression of
cytokine transcripts as well as inducible cytokine production [24].
In fact, phenotypically polarized macrophages have been broadly
classified into two main groups: classically activated (M1)
macrophages and alternatively activated (M2) macrophages that
are further subdivided into three subtypes [25]. Moreover, M1
macrophages exhibit an anti-angiogenic phenotype, whereas M2
macrophages exhibit a pro-angiogenic phenotype [22–27]. It is
therefore possible that individuals with macrophages of one
activation state will have a relative protective effect in AMD while
individuals with macrophages of another activation state will be at
risk for progressive complications. This idea is supported by our
observation that the presence of highly activated macrophages is
associated with a 5-fold increase in risk of having wet AMD [24].
The mechanism of macrophage activation is clearly multifac-
torial involving genetics, systemic health cofactors, and environ-
mental cofactors including infection [15,28–30]. Infectious
pathogens have been implicated in several vascular diseases,
especially atherosclerosis [29–32]. Chlamydia pneumoniae, human
cytomegalovirus (HCMV), and Helicobacter pylori all have been
implicated in promoting severity of atherosclerosis and inducing
complications such as myocardial infarction [31,33,34]. These
findings prompted us to perform a seroepidemiologic study to
investigate a possible association for these infectious pathogens
with neovascular AMD, a study that subsequently demonstrated a
significant association with high HCMV IgG serum titers [35].
This finding differed from that of Kalayoglu and coworkers [36]
whose study suggested an association between chlamydia and
neovascular AMD.
Given our clinical findings [35] and our long-standing interests
in the immunology and pathogenesis of cytomegalovirus retinal
disease [37], we sought to test the hypothesis that chronic infection
with HCMV, a common b-herpesvirus that targets myeloid
lineage cells that give rise to activated macrophage cell populations
in tissues [38], is a heretofore unrecognized risk factor for onset
and progression of neovascular AMD. This hypothesis was tested
herein using an established mouse model of laser-induced CNV
[39] to evaluate the effect of systemic infection by murine
cytomegalovirus, a mouse b-herpesvirus whose genomic structure
and cellular/tissue tropisms parallels those of HCMV [38], on the
severity of CNV lesions during acute and chronic virus infection.
We observed that mice with chronic MCMV infection developed
more severe CNV, and that macrophages collected from
chronically infected animals were activated as determined by
expression of high levels of transcripts for a number of pro-
inflammatory and pro-angiogenic factors, especially the pro-
angiogenic cytokine vascular endothelial growth factor (VEGF). In
vitro studies confirmed that MCMV infection of a mouse
macrophage cell line resulted in significant upregulation of VEGF
mRNA and VEGF protein production. Subsequent in vivo and in
vitro studies using the antiviral ganciclovir demonstrated that
increased production of VEGF by splenic macrophages collected
from chronically infected mice and by MCMV-infected mouse
macrophages grown in culture was ganciclovir-sensitive, findings
that suggest that active virus replication is indeed required for
stimulation of VEGF production by macrophages.
Results
Mice with chronic systemic MCMV infection develop
more severe experimental CNV
We first explored the effect of systemic MCMV infection on
experimental CNV. Three times relative to systemic virus
inoculation were chosen for this study, one at time of acute
systemic infection (6 days postinfection) and two at times of
chronic systemic infection (6 weeks postinfection and 12 weeks
postinfection) [38]. Groups of C57BL/6 mice were inoculated
intraperitoneally with a sublethal dose of MCMV, and their eyes
were subjected to laser-induced CNV [39] at 6 days, 6 weeks, or
12 weeks after systemic MCMV infection. In this study, control
mice received UV-inactivated MCMV. Four weeks after laser
treatment, propidium iodide-stained flatmounts of the posterior
pole were prepared of all laser-treated eyes, and groups were
compared for severity of CNV. Results are shown in Figure 1A–D
and Figure 2A. As expected, mice inoculated with UV-inactivated
MCMV exhibited small CNV lesions (1.860.1 disc areas). In
comparison, mice inoculated with infectious MCMV exhibited
CNV lesions of increased size. Lesion size also increased with time
after MCMV infection. Whereas mice with MCMV infection of 6-
days duration exhibited CNV lesions of moderate enlargement
(2.760.2 disc areas) four weeks after laser treatment, progressively
larger lesions were observed in mice with MCMV infection of 6-
weeks (3.160.2 disc areas) and 12-weeks (4.460.6 disc areas)
duration prior to laser treatment (Figure 2A). A statistical
comparison of lesion sizes observed in animals with MCMV
infection of 12-weeks duration versus control animals revealed
Author Summary
Neovascular age-related macular degeneration (AMD) is
the leading cause of vision loss in the elderly. Onset of
AMD is due to local production of vascular endothelial
growth factor (VEGF) that promotes formation of new
blood vessels in the retina, thereby leading to retinal tissue
destruction and blindness. Since a clinical study by us
showed that AMD patients have high amounts of
antibodies to human cytomegalovirus (HCMV), we postu-
lated that infection with HCMV might be a risk factor for
AMD. To investigate this possibility, mice were infected
with murine cytomegalovirus (MCMV), and at various times
after infection, subjected to laser treatment of the eye to
induce choroidal neovascularization, an experimental
model of AMD. Most severe CNV developed in mice with
chronic MCMV infection, a time when MCMV gene
sequences could not be detected within eye tissues.
However, splenic macrophages collected from mice with
chronic MCMV infection produced high levels of gene
transcripts to several pro-angiogenic factors including
VEGF. MCMV infection of mouse macrophages in culture
also produced high amounts of VEGF. Stimulation of VEGF
production in vivo and in vitro was sensitive to antiviral
treatment. Chronic HCMV infection may therefore promote
AMD by stimulation of VEGF production by activated
macrophages.
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increased with progression of MCMV. Whereas only 10% of the
total number of lesions in mice inoculated with UV-inactivated
virus exceeded 2.2 disc areas (Figure 2B) (representing the 95%
confidence interval for lesion size in control mice), 57.5, 92, and
100% of animals with systemic MCMV infection of 6-days, 6-
weeks, and 12-weeks duration prior to laser treatment, respective-
ly, developed large CNV lesions. Similar findings were observed
when flatmounts were evaluated for degree of vascular size
(Figure 2C) and vascularity (data not shown), although cellular
density remained constant (Figure 2D). Taken together, these
results suggest that systemic MCMV infection results in more
severe CNV in mice, even during acute infection where a trend in
increased severity is also observed. The most severe and
Figure 1. Eyes of mice with chronic MCMV infection show more severe CNV as determined by flatmount preparations. Groups of
adult C57BL/6 mice were inoculated intraperitoneally with either MCMV or UV-inactivated virus. At 6 days, 6 weeks, or 12 weeks after inoculation, all
mice were subjected to laser treatment to induce CNV, and, four weeks later, flatmount preparations of the posterior pole of mouse eyes were
stained with propidium iodide. Flatmount preparations of representative individual mouse eyes showing areas of CNV (white outlines). (D=Optic
Disc) (Magnification=506) (Bar=100 um)) (A) Mouse inoculated with UV-inactivated MCMV (control) for 12 weeks prior to laser treatment. (B) Mouse
infected with MCMV for 6 days prior to laser treatment. (C) Mouse infected with MCMV for 6 weeks prior to laser treatment. (D) Mouse infected with
MCMV for 12 weeks prior to laser treatment.
doi:10.1371/journal.ppat.1002671.g001
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with chronic MCMV infection of 12-weeks duration.
Histopathologic analysis of CNV lesions (Figure 3A) paralleled
those of flatmount findings. When compared with mice that
received UV-inactivated virus (Figure 3B), mice with laser-induced
CNV at 12 weeks after infection demonstrated a near doubling of
CNV surface area (64,97767,267 pixels
2 versus 119,14968,578
pixels
2; p=,0.0004). Importantly, neither active nor chronic
systemic MCMV infection changed the typical morphological
appearance of experimental CNV. There was an absolute absence
of MCMV-induced cytopathology as well as retinal necrosis.
MCMV IE1 and gH DNA cannot be detected in choroidal
tissues of chronically infected mice with the most severe
choroidal neovascularization
Since systemic MCMV infection was found to induce more
severe CNV, we explored the possibility that direct virus infection
of choroidal tissues might be responsible for this outcome.
Choroidal tissues as well as several key tissues and cell populations
known to be associated with MCMV pathogenesis [38,40] were
sampled for detection of MCMV DNA using primers for virus-
specific immediate-early 1 (IE1) and glycoprotein H (gH) gene
sequences in PCR assays. As expected, samples of spleen tissue,
lung tissue (Figure 4), and salivary gland tissue as well as splenic
macrophages collected from animals at time of acute MCMV
infection (6 days postinfection) or chronic MCMV infection (12
weeks postinfection) provided positive signals for MCMV-specific
DNA (Table 1) indicating extensive systemic MCMV infection.
Purified CD34+ cells of bone marrow origin collected from mice
with acute and chronic MCMV infection were also positive for
MCMV DNA. In comparison, choroidal tissues from eyes of
acutely infected mice were indeterminant for MCMV-specific
DNA, and MCMV-specific DNA sequences could not be detected
in choroidal tissues from eyes of chronically infected animals
(Table 1). The apparent lack of MCMV infection of choroidal
tissues taken from chronically infected animals was confirmed by
our inability to recover infectious virus from whole eyes of parallel
groups of chronically infected animals individually homogenized
and individually inoculated onto MEF monolayers. Thus, no
evidence was found for direct MCMV infection of choroidal
tissues or subsequent active virus replication within the eye at time
of chronic infection when CNV was found to be most severe.
Figure 2. Comparative quantitative analysis of flatmount preparations of eyes of all mice of each group confirm that chronic MCMV
infection results in more severe CNV. Groups of adult C57BL/6 mice were inoculated intraperitoneally with either MCMV or UV-inactivated virus
(control). At 6 days, 6 weeks, or 12 weeks after inoculation, all mice were subjected to laser treatment to induce CNV, and. four weeks. later flatmount
preparations of the posterior pole of mouse eyes were stained with propidium iodide and assessed for different parameters of CNV severity. Asterisks
indicate statistical significance when compared with control (p=,0.0001). (A) Comparison of cellular margins (lesion size). (B) Comparison of
frequency of large lesions (.2.2 disc areas). (C) Comparison of vascular area (disc areas). (D) Comparison of cellular density index.
doi:10.1371/journal.ppat.1002671.g002
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systemic MCMV infection are activated and produce high
amounts of VEGF mRNA
Alternatively, systemic MCMV infection could contribute to
increased severity of CNV indirectly via activation of macrophages
to produce pro-angiogenic factors. It is well known for both HCMV
and MCMV that peripheral blood monocytes are vehicles for
systemic dissemination of virus during acute infection [38,40], and
these cells can harbor virus during chronic infection and with the
potential to become activated macrophages within various tissues
[23]. Since sufficient numbers of macrophages could not be
collected from individual eyes of acutely and chronically infected
mice for analysis, we subjected enriched populations of splenic F4/
80+ macrophages collected from acutely and chronically infected
mice to real time RT-PCR assay for detection and quantification of
transcripts to several pro-inflammatory and pro-angiogenic cyto-
kines and mediators associated with neovascular AMD. In this
study, results were compared with baseline transcript levels
established for splenic macrophages collected from mice inoculated
with UV-inactivated virus. As shown in Table 2, significant
differences were observed in the patterns of synthesis for a number
of macrophage-associated transcripts examined during acute and
chronic MCMV infection. Of importance was the finding of
significant upregulation of VEGF (p=0.04) and VEGFR1 (p=0.05)
transcripts that progressed from acute to chronic infection. Thiswas
associated with a concomitant significant upregulation of matrix
metalloproteinase-9 (MMP-9) (p=0.02),cyclooxygenase-2 (COX-2)
(p=0.05), and tumor necrosis factor alpha (TNF-a)( p=0.03)
transcripts, but only during chronic infection. Interestingly,
macrophage-associated VEGFR2 transcript was significantly
downregulated (p=0.01) during acute and chronic infection. These
results suggest that an increase in CNV size and severity during
chronic MCMV infection may be due to virus-induced activation of
macrophages that favor neovascularization.
Figure 3. Eyes of mice with chronic MCMV infection show more
severe CNV as determined by histopathologic analysis. Groups
of adult C57BL/6 mice were inoculated intraperitoneally with either
MCMV or UV-inactivated virus. At 6 days, 6 weeks, or 12 weeks after
inoculation, all mice were subjected to laser treatment to induce CNV,
and, four weeks later, retinal sections were subjected to histopathologic
analysis. (A) Hematoxylin and eosin-stained histopathologic sections of
representative individual mouse retinas four weeks after laser treatment
s h o w i n ga r e a so fC N V( w h i t eo u t lines and arrows). (Magnifica-
tion=1006) Mouse inoculated with UV-inactivated MCMV (control);
mouse infected with MCMV for 6 days prior to laser treatment; mouse
infected with MCMV for 6 weeks prior to laser treatment; mouse
infected with MCMV for 12 weeks prior to laser treatment. (B)
Comparative quantitative analysis of all animals of each group for size
of CNV areas as determined by histopathologic analysis. Asterisk
indicates statistical significance when compared with control
(p=,0.0004).
doi:10.1371/journal.ppat.1002671.g003
Figure 4. Lung tissues collected from chronically infected mice
are positive for MCMV-specific IE1 DNA sequences. Represen-
tative 1% agarose gel showing positive signal for PCR assay for MCMV-
specific IE1 gene sequences performed on three samples of lung tissue
collected from three mice infected with MCMV for 12 weeks.
(M=Molecular weight standards).
doi:10.1371/journal.ppat.1002671.g004
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macrophages stimulates production of VEGF mRNA and
VEGF protein
Although splenic macrophages collected from mice with chronic
systemic MCMV infection exhibited an approximate 20-fold
increase in VEGF mRNA levels when compared with splenic
macrophages collected from control mice, it is possible that
increased VEGF mRNA production was not due to active MCMV
replication. To explore directly the ability of mouse macrophages
to produce increased amounts of VEGF during active virus
replication, monolayers of IC-21 mouse macrophages, a macro-
phage cell line of C57BL/6 origin [41], were either mock-infected
(control), treated with LPS (positive control), inoculated with UV-
inactivated MCMV (negative control), or inoculated with
infectious MCMV at a dose resulting in a low level of infection
(2.5 PFU/cell). All monolayers were quantified at 24 hr and 48 hr
later for levels of TNF-a mRNA and VEGF mRNA by
quantitative RT-PCR assay. Results are shown in Figure 5A.
When compared with mock-infected monolayers, monolayers of
IC-21 mouse macrophages were activated by LPS treatment as
demonstrated by large increases in VEGF mRNA and TNF-a
mRNA levels, but parallel monolayers inoculated with UV-
inactivated virus produced only low levels of VEGF mRNA and
TNF-a mRNA suggesting little-to-no activation. In comparison,
MCMV-infected monolayers of IC-21 mouse macrophages at
24 hr postinfection showed a 13-fold increase in VEGF mRNA
levels, but interestingly failed to duplicate an increase in TNF-a
mRNA production as seen in LPS-treated MCMV-infected
monolayers. The same pattern of cytokine mRNA synthesis was
observed in MCMV-infected IC-21 mouse macrophages at 48 hr
postinfection. At this time after virus infection, VEGF mRNA
levels were .50-fold greater than levels found in mock-infected
monolayers (p=,0.04), but TNF-a mRNA levels were only ,3-
fold greater. This pattern of activation is consistent with a M2
phenotype of macrophage activation [25] since further analysis of
MCMV-infected IC-21 macrophages when compared with mock-
infected cells revealed increased levels of IL-10 and IL-1RA
mRNA levels, equivalent levels of IL-23 mRNA production, and
no detectable IL-21 mRNA production (data not shown).
Confirmation that MCMV infection of IC-21 mouse macrophages
resulted not only in a significant increase in VEGF mRNA levels,
but also in a significant increase in VEGF protein, was provided by
ELISA analysis of supernatants collected at 48 hr postinfection
(p=0.01) (Figure 5B). Taken together, these results provide proof-
of-principal that the increase in VEGF mRNA levels observed in
mice with chronic systemic infection could arise from direct
MCMV infection, active virus replication, and subsequent
Table 1. PCR assay analysis for MCMV-specific IE1 and gH DNA in various cells and tissues collected from mice infected with
MCMV for 6 days (acute infection) or 12 weeks (chronic infection).
Acute MCMV infection (6 days postinfection) Chronic MCMV infection (12 weeks postinfection)
Choroidal tissue +/2 None detected
Splenic macrophages ++
Whole spleen ++
Bone marrow cells (CD34+ cells) ++
Salivary gland tissue ++
Lung tissue ++
doi:10.1371/journal.ppat.1002671.t001
Table 2. Macrophage mRNA levels for various cytokines and mediators relevant to CNV formation following acute or chronic
MCMV infection.
mRNA levels
(splenic macrophages) UV-inactivated controls
Acute MCMV infection (6 days
postinfection)
Chronic MCMV infection (12 weeks
postinfection)
TNF-a 100% 77% 186% *
VEGF 100% 1,270% * 2,090% *
VEGFR1 100% 398% * 431% *
VEGFR2 100% 14% * 30% *
MMP-9 100% 32% 344% *
COX-2 100% 177% 489% *
iNOS 100% 122% 157%
PDGF-b 100% 41% 91%
Populations of splenic macrophages collected from groups of mice with acute MCMV infection (6 days postinfection) and chronic MCMV infection (12 weeks
postinfection) were compared with splenic macrophages collected from groups of mice inoculated with UV-inactivated MCMV for 6 days or 12 weeks duration for
mRNA levels to various pro-inflammatory and pro-angiogenic cytokines and mediators associated with neovascular AMD. These included tumor necrosis factor-alpha
(TNF-a), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2),
matrix metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and platelet-derived growth factor-beta (PDGF-b). Baseline
transcript levels for splenic macrophages collected from groups of mice inoculated with UV-inactivated mice for 6 days or 12 weeks was were set at 100%. Asterisks
indicate statistical significance when compared with parallel control groups.
doi:10.1371/journal.ppat.1002671.t002
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angiogenic phenotype [25].
To further explore VEGF production by MCMV-infected
mouse macrophages in culture, monolayers of IC-21 mouse
macrophages were either MCMV-infected (2.5 PFU/cell) or
mock-infected and subjected to immunostaining analysis for
detection of VEGF production and for quantification of VEGF-
positive cells at 24 hr and 48 hr postinfection. Results are shown
in Figure 6. When compared with MCMV-infected and mock-
infected cells reacted with control antibody, MCMV-infected cells
reacted with anti-VEGF antibody at 24 hr and 48 hr postinfection
exhibited positive cytoplasmic staining for VEGF. Whereas
staining was generally stronger in MCMV-infected cells at 48 hr
postinfection when compared with MCMV-infected cells at 24 hr
postinfection, the strongest staining was observed in foci of
MCMV-infected cells at 48 hr postinfection showing early stages
of cytopathology during plaque formation. It is noteworthy that
individual macrophages at 48 hr postinfection not involved in
plaque formation were also VEGF positive. Quantification studies
revealed that ,55% and ,93% of MCMV-infected IC-21 mouse
macrophages exhibited positive staining for VEGF at 24 hr and
48 hr postinfection, respectively, whereas mock-infected controls
showed background levels of VEGF production of ,10%.
Production of VEGF mRNA by splenic macrophages
collected from chronically infected mice and production
of VEGF mRNA and VEGF protein by MCMV-infected
mouse macrophages in culture is ganciclovir sensitive
We found in studies described above that splenic macrophages
collected from acutely infected mice and chronically infected mice
produced significantly more VEGF mRNA when compared with
splenic macrophages collected from control mice (Table 2). In
addition, monolayers of MCMV-infected IC-21 mouse macro-
phages produced significantly more VEGF mRNA and VEGF
protein when compared with monolayers of mock-infected cells
(Figures 5–6). If stimulation of VEGF production in vivo and in
vitro is induced directly by active virus replication, we hypothe-
sized that stimulation of VEGF production should be sensitive to
treatment with ganciclovir, an antiviral that inhibits HCMV and
MCMV replication at the level of virus DNA synthesis [42,43]. To
test this hypothesis in vivo, a study was performed in which groups
of C57BL/6 mice were either inoculated intraperitoneally with a
sublethal dose of MCMV or mock-infected with maintenance
medium (control). Unlike the study summarized in Table 2, it is
noteworthy that this study did not use inoculation with UV-
inactivated virus as a control. At 12 weeks postinfection, groups of
MCMV-infected mice or mock-infected mice were treated
intraperitoneally with ganciclovir (40 mg/kg/day) for 7 days
[43]. Parallel groups of untreated control MCMV-infected mice or
mock-infected mice were not treated with ganciclovir, but instead
received daily intraperitoneal injections of phosphate-buffered
saline for 7 days. Following the 7-day regimen of ganciclovir or
phosphate-buffered saline treatment, splenic macrophages were
collected from ganciclovir-treated and untreated chronically
infected mice and compared by quantitative real time RT-PCR
assay for levels of VEGF mRNA and TNF-a mRNA. In
agreement with our previous study summarized in Table 2,
splenic macrophages collected from untreated chronically infected
mice showed dramatic stimulation of VEGF mRNA production as
well as TNF-a mRNA production (Figure 7). In fact, the degree of
stimulation for both VEGF mRNA and TNF-a mRNA produc-
tion was greater than that observed in our previous study (Table 2),
especially with respect to TNF-a mRNA production. This
difference might be due to the different controls used in the two
separate studies, UV-inactivated virus (Table 2) versus mainte-
nance medium (Figure 7). When compared with untreated virus-
infected animals, however, ganciclovir treatment resulted in a
significant inhibition of VEGF mRNA production (p=#0.009),
specifically an approximate 44-fold decrease in VEGF mRNA
production. A similar degree of inhibition of TNF-a mRNA
production was also observed in the presence of ganciclovir
treatment (p=#0.009). Importantly, this significant inhibition of
VEGF mRNA and TNF-a mRNA production in ganciclovir-
treated animals could not be attributed to drug-related toxicity
since splenic macrophages collected from these animals were
found to be .95% viable at time of enrichment and just prior to
RT-PCR assay when analyzed by the trypan blue exclusion and
MTS assays (data not shown).
Figure 5. MCMV infection stimulates production of VEGF
mRNA and VEGF protein in monolayers of IC-21 mouse
macrophages. Monolayers of IC-21 mouse macrophages were either
mock infected or infected with MCMV (2.5 PFU/cell) and analyzed for
amounts of VEGF mRNA and VEGF protein at 24 hour and/or 48 hour
postinfection. Asterisks indicate statistical significance when compared
with mock-infected monolayers. (A) Quantitative RT-PCR assay for VEGF
mRNA (black bars) and TNF-a mRNA (gray bars) in monolayers of IC-21
macrophages either mock-infected, treated with LPS, inoculated with
UV-inactivated virus, or infected with MCMV at 24 hr or 48 hr after
infection and compared with mock-infected monolayers. (p=#0.04) (B)
ELISA for VEGF protein (black bars) in monolayers of IC-21 macrophages
infected with MCMV at 48 hr postinfection and compared with mock-
infected monolayers (p=0.01).
doi:10.1371/journal.ppat.1002671.g005
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ganciclovir treatment findings. Monolayers of IC-21 mouse
macrophages were inoculated with either a low dose of MCMV
(2.5 PFU per cell) or mock-infected, and all monolayers were
treated at 1 hour postinfection with either 0, 15, 30, or 60 uM of
ganciclovir. At 24 hr postinfection, all monolayers were harvested
and subjected to quantitative RT-PCR assay for comparison of
VEGF mRNA levels. In agreement with in vivo ganciclovir
treatment findings, increasing amounts of the antiviral reduced in
a relatively dose-dependent manner the amounts of VEGF mRNA
produced when compared with untreated MCMV-infected mouse
macrophages (Figure 8A). As expected, untreated MCMV-
infected mouse macrophages produced VEGF mRNA at
increased levels, and at levels equivalent to that observed for
MCMV-infected macrophages at 24 hr postinfection as shown in
Figure 5A. With increasing doses of ganciclovir, however, amounts
of VEGF mRNA were dampened, ultimately being reduced by
,5-fold at the highest doses of ganciclovir, 30 and 60 uM. This
reduction in VEGF mRNA production could not be attributed to
drug-induced toxicity since mock-infected ganciclovir-treated IC-
21 mouse macrophages remained .95% viable at all doses tested
when subjected to the trypan blue exclusion and MTS assays (data
not shown).
Since ganciclovir treatment appeared to reduce, but not
eliminate, VEGF mRNA production by MCMV-infected IC-21
mouse macrophages in a relatively dose-dependent manner, we
sought to determine if VEGF could be detected within ganciclovir-
treated MCMV-infected IC-21 mouse macrophages, albeit at
reduced levels, with increasing doses of drug. We therefore
performed an immunostaining study to visualize VEGF produc-
tion within monolayers of MCMV-infected IC-21 mouse macro-
phages at 24 hr postinfection following treatment with 0, 15, 30,
or 60 uM of ganciclovir at 1 hr after virus inoculation. Results are
shown in Figure 8B. In agreement with previous findings (Figure 6),
MCMV-infected IC-21 mouse macrophages not treated with drug
exhibited prominent cytoplasmic staining for VEGF. In compar-
ison, increasing doses of ganciclovir treatment appeared to
dampen VEGF protein production within the MCMV-infected
cells. Nonetheless, positive staining for VEGF could still be
detected within MCMV-infected IC-21 mouse macrophages
treated with the highest dose of ganciclovir, 60 uM. Only faint
background staining or no detectable staining was observed in
parallel control monolayers of mouse macrophages that were
either not infected with virus or virus-infected and reacted with
control antibody (data not shown). Taken together, these in vitro
findings suggest that VEGF mRNA and VEGF protein production
during MCMV infection of IC-21 mouse macrophages are indeed
ganciclovir-sensitive, although VEGF production is not completely
eliminated in the presence of the antiviral. Moreover, the
significant reduction of VEGF mRNA and VEGF protein during
ganciclovir treatment of MCMV-infected IC-21 mouse macro-
phages in culture is in agreement with in vivo findings, thereby
Figure 6. MCMV infection of monolayers of IC-21 mouse macrophages results in VEGF production by virus-infected and bystander
uninfected cells. Monolayers of IC-21 mouse macrophages were either mock infected or infected with MCMV (2.5 PFU/cell). At 24 hour
postinfection (MCMV 24 hr pi) or 48 hour postinfection (MCMV 48 hr pi), all mock-infected and MCMV-infected cells were harvested, fixed, and
reacted with either control rabbit IgG or anti-VEGF rabbit IgG as primary antibody for visualization of VEGF production. All cells were counterstained
with DAPI to visualize cell nuclei. VEGF=Red; DAPI=Blue (Magnification=2006) White circle emphasizes focus of cells at 48 hr postinfection
undergoing cytopathology and plaque formation. Quantification of cells exhibiting positive staining for VEGF was accomplished by using mean
values of the number of cells showing obvious red cytoplasmic staining within five random microscopic fields of view.
doi:10.1371/journal.ppat.1002671.g006
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within splenic macrophages collected from MCMV-infected mice
with chronic infection is due to active virus replication.
Discussion
The number of investigations of angiogenesis in the eye has
increased significantly in recent years due to findings that
neovascularization of the retina and choroid plays a central role
in the development of a number of major blinding diseases. These
include AMD as well as diabetic retinopathy, polypoidal choroidal
vasculopathy, myopic choroidal neovascularization, neovascular
glaucoma, retinopathy of prematurity, and ocular tumorigenesis
(all reviewed in [44]). Since a seroepidemiologic clinical study by
us demonstrated an apparent association between HCMV
infection and neovascular AMD [35], we used an experimental
C57BL/6 mouse model of CNV to test the hypothesis that
systemic MCMV infection will contribute to the severity of CNV.
It has not escaped our attention that mouse strain-dependent
factors might play a factor in CNV development during systemic
MCMV infection since macrophages from C57BL/6 mice (a
prototypical Th1 mouse strain) and macrophages from BALB/c
mice (a prototypical Th2 mouse strain) exhibit distinct M1- or M2-
dominant responses [45]. Nonetheless, our results collectively
showed that systemic MCMV infection of C57BL/6 mice did
indeed result in more severe CNV, and, more importantly,
chronically infected mice showed the greatest severity of CNV.
Although MCMV DNA sequences could not be detected within
choroidal tissues of chronically infected animals, splenic macro-
phages collected from chronically infected animals produced
increased amounts of transcripts to several pro-inflammatory and
pro-angiogenic cytokines including VEGF. That MCMV infection
of mouse macrophages will modulate a pro-angiogenic M2
phenotype that included significant stimulation of VEGF produc-
tion was shown directly by in vitro studies using a mouse
macrophage cell line of C57BL/6 origin. Further evidence that
virus infection induced stimulation of VEGF production both in
vivo and in vitro was provided by ganciclovir treatment studies
that demonstrated sensitivity of VEGF production to the antiviral
both in vivo and in vitro. Thus, our findings are novel with respect
to chronic eye disease since they provide for the first time new data
that suggests that chronic cytomegalovirus infection can contribute
to the pathogenesis of wet AMD, possibly via activation of
Figure 7. Ganciclvir treatment reduces levels of VEGF mRNA
and TNF-a mRNA production by splenic macrophages col-
lected from chronically infected mice. Groups of adult C57BL/6
mice were inoculated intraperitoneally with either MCMV or mock-
infected with maintenance medium. At 12 weeks after inoculation,
groups of MCMV-infected or mock-infected mice were treated
intraperitoneally with ganciclovir for 7 days (40 mg/kg/day). Parallel
groups of untreated control MCMV-infected or mock-infected mice
received daily intraperitoneal injections of phosphate-buffered saline
for 7 days. Following the 7-day regimen of ganciclovir or phosphate-
buffered saline treatment, splenic macrophages were collected from
treated and untreated MCMV-infected animal groups and compared
with splenic macrophages collected from treated and untreated mock-
infected animal groups by quantitative real-time RT-PCR assay for
comparison of levels of TNF-a mRNA and VEGF mRNA production.
Asterisks indicate statistical significance when compared with parallel
treated or untreated mock-infected animals. (p=#0.009). Gray
bars=TNF-a mRNA; Black bars=VEGF mRNA.
doi:10.1371/journal.ppat.1002671.g007
Figure 8. Ganciclvir treatment reduces levels of VEGF mRNA production by MCMV-infected IC-21 macrophages. Monolayers of IC-21
mouse macrophages were either mock infected or infected with MCMV (2.5 PFU/cell), treated at 1 hour postinfection with 0, 15, 30, or 60 uM of
ganciclovir, and harvested at 24 hour postinfection. (A) Quantitative real-time PCR assay for comparison of levels of VEGF mRNA production. Three
independent experiments were performed. (B) Immunostaining for detection of cytoplasmic VEGF production. VEGF=Red; DAPI=Blue
(Magnification=2006).
doi:10.1371/journal.ppat.1002671.g008
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of VEGF production. While we have not yet demonstrated in our
model direct visualization of MCMV-infected, VEGF-producing
macrophages associated with areas of CNV, several observations
would argue that this is a likely occurrence. Firstly, we [19] and
others [20] have shown previously that macrophages are essential
for development of CNV. Secondly, we have shown previously in
the context of MCMV retinitis that IC-21 macrophages infected
with a b-galactsidase-expressing LacZ recombinant MCMV will
travel to ocular tissues of C57BL/6 mice following tail vein
injection [46]. Finally, we show herein that MCMV infection of
IC-21 macrophages stimulates VEGF production, a stimulation
that is also observed in splenic macrophages collected from
chronically infected mice with severe CNV. Future in vivo
immunostaining studies will directly address this important issue.
The concept that infectious agents might contribute to the
pathogenesis of vascular diseases has become an intense and
controversial area of investigation. Two major hypotheses have
emerged. One hypothesis proposes that vascular disease is caused
by direct infection of the target tissue [36], while the second
hypothesis proposes a bystander effect caused by infection at a
distant tissue [47–49]. In atherosclerosis, direct infection of the
atheromatous plaque by Chlamydia pneumoniae has been suggested as
a stimulus for recruitment of inflammatory cells. Arguing against
this hypothesis, however, are antibiotic treatment trials designed to
suppress Chlamydia pneumoniae infection and failing to demonstrate a
measurable clinical effect on preventing myocardial infarction or
other sequelae [34]. On the other hand, patients with chronic
periodontal infection and inflammation have provided evidence
suggesting that chronic infection at a distant site may play a role in
vascular disease. In this patient population, infection by a variety
of different organisms appeared to lead to more severe vascular
disease [34,50,51]. Since in our study, MCMV-specific DNA
sequences could not be detected in choroidal tissues of eyes with
the most severe choroidal neovascularization, we propose a similar
bystander hypothesis for the role of HCMV infection in chroroidal
neovascularization of the eye.
HCMV is a common b-herpesvirus that persists for the life of its
host following primary infection. While chronic HCMV infection
of healthy, immunologically normal persons was initially thought
to have no significant disease consequence, chronic HCMV
infection has now been associated with a growing number of long-
term diseases that include the vascular disease atherosclerosis,
restenosis following angioplasty, transplant vascular sclerosis
associated with chronic allograft rejection of solid organ grafts
(reviewed in [52]), and possibly tumor formation (reviewed in
[53]). Evidence for a link between HCMV and vascular disease
was first provided by Melnick, DeBakey, and coworkers [54] when
virus antigen was detected within arterial tissues from carotid
artery plaques obtained from patients with atherosclerosis. Since
this fundamental observation of ,20 years ago, however, it has
been difficult to determine the precise mechanisms by which
HCMV might participate in the pathophysiology of vascular
disease because the etiologies of chronic diseases are complex and
multifactorial. Nonetheless, seropositive HCMV persons are two
to three-times more likely to develop coronary artery disease when
compared with HCMV seronegative patients [55]. In support of
this association are recent findings that 76% of patients with
ischemic heart disease have detectable HCMV DNA within their
vascular tissues [56], and up to 53% of carotid artery
atherosclerotic lesions are positive for HCMV DNA [57]. A
number of animal studies have also provided compelling evidence
that cytomegalovirus plays an important role in the pathophysi-
ology of atherosclerosis, including several studies that have
demonstrated more severe atherosclerosis in apoE 2/2 mice
following systemic MCMV infection [58–61].
While an association has been recognized between cytomega-
lovirus infection and atherosclerosis, the strongest association of
cytomegalovirus in vascular disease is with the development of
restenosis and transplant vascular sclerosis. Several clinical studies
have shown that HCMV infection is involved in accelerating both
acute and chronic graft failure in all types of solid organ
transplants by promoting vascular disease associated with rejection
[52], probably by virus originating from the vasculature of
transplanted organs from HCMV seropositive donors [62]. For
example, HCMV infection was shown to double the 5-year rate of
graft failure in cardiac allograft recipients due to accelerated
transplant vascular sclerosis [63]. Similarly, kidney transplant
allograft survival was decreased in asymptomatic HCMV-infected
recipients during the first 100 days after transplantation when
compared with recipient patients who had no evidence for HCMV
infection, an outcome suggesting that HCMV infection, even
when asymptomatic, has a negative impact on graft survival [64].
These clinical findings have been supported by a number of rat
models of heart, kidney, lung, and small bowel transplantation in
which infection with rat cytomegalovirus (RCMV) significantly
decreased the mean time to graft failure while concomitantly
increasing the degree of vasculopathy within the allograft tissue
[65,66].
Neovascularization is a complex, multi-step process of angio-
genesis that rapidly takes place in response to inflammation and
tissue injury, and involves many cell types, cytokines, chemokines,
and proteases that work in concert to form new blood vessels from
existing blood vessels. In brief (reviewed in [52]), angiogenesis is
initiated by release of pro-angiogenic factors from activated
endothelial cells and tissue-resident macrophages, followed by
removal of pericytes that surround the existing blood vessels. This
results in the breakdown of the basement membrane of the existing
blood vessel wall through activation of several proteases including
matrix metalloproteinases (MMPs). The release of extracellular
remodeling proteins during continued degradation of the blood
vessel wall leads to the release of growth factors that promote
endothelial cell migration toward the angiogenic stimulus and
ultimately mediates endothelial cell proliferation that drives the
formation of neotubules. These neotubules in turn release
additional growth factors such as platelet-derived growth factor
(PDGF) that recruit vascular smooth muscle cells and pericytes
that stabilize the newly formed blood vessel. Importantly, pro-
angiogenic M2 macrophages have been shown recently to act as
bridging cells that promote the fusion of neotubules into one
continuous blood vessel [67]. Cytomegalovirus infection could
therefore enhance neovascularization at various stages of angio-
genesis through a number of direct and indirect mechanisms.
Monocytes are the primary target in vivo for HCMV (and
MCMV and RCMV) infection [68,69]. They serve as a site for
virus latency and persistence [70], and help to disseminate virus
throughout the host including the vasculature. When virus-
infected monocytes enter the vasculature, they mature, and during
the maturation process to become macrophages, they initiate an
activation program that also serves to stimulate virus replication
[71]. In this manner, infected macrophages may disseminate virus
to other cells of the vasculature that are involved in angiogenesis
and vascular disease. These include endothelial cells, smooth
muscle cells, pericytes, and fibroblasts [52]. Given this complexity,
the precise temporal relationship between virus infection of
individual cell types and disease pathogenesis remains obscure
and difficult to determine. Nonetheless, it is known that HCMV
infection of endothelial cells induces the expression of adhesion
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transendothelial cell migration of inflammatory cells including
monocytes. These monocytes become resident macrophages that
promote angiogenesis by secretion of VEGF and other pro-
angiogenic factors such as IL-6 [52].
During virus replication, the HCMV-encoded chemokine
receptor US28 also plays a prominent yet multifaceted role in
angiogenesis. Firstly, US28 has been shown to stimulate VEGF
production directly by induction of COX-2 via activation of the
NF-kB pathway [73]. Secondly, this HCMV-encoded chemokine
receptor promotes the migration of macrophages in response to
the CX3CL1 chemokine Fractalkine [52], a function that may
help to attract additional HCMV-infected macrophages to areas of
inflammation and thereby amplify angiogenesis. Thirdly, US28
also promotes the migration of vascular smooth muscle cells [74],
but does so by binding to CC-chemokines and not Fractalkine
[75]. Thus, US28 appears to stimulate the migration of both
macrophages and vascular smooth muscle cells, but in a ligand-
dependent manner. Whereas US28-induced migration of macro-
phages takes place after ligation with Fractalkine, but not CC-
chemokines, US28-induced migration of vascular smooth muscle
cells is mediated by binding to CC-chemokines, but not
Fractalkine. Since HCMV-encoded US28 apparently plays
multiple roles in promoting angiogenesis, we postulate the same
is true for M33, the MCMV homologue of US28 [76]. Ongoing
studies are therefore oriented toward testing the hypothesis that
MCMV-encoded M33 plays significant roles in the pathophysi-
ology and increased severity of CNV during chronic MCMV
infection.
Additional direct and indirect mechanisms by which cytomeg-
alovirus might contribute to angiogenesis and vascular disease are
suggested by other studies. Examples include studies that have
shown that HCMV infection induces a reduction of endothelial
nitric oxide synthase activity commonly observed during cardio-
vascular disease [77]; RCMV induces the stimulation of a number
of proteases including MMPs that are involved in degradation of
the basement membrane required during the angiogenesis process
[78]; HCMV induces an upregulation of a number of cellular
chemokines including macrophage inflammatory protein 1 alpha
(MIP1-a), MIP1-b, RANTES, and IL-2 that play critical roles in
angiogenesis and development of vascular disease [74,79]; and
HCMV infection of coronary artery smooth muscle cells stimulates
VEGF expression [80].
Since angiogenesis in health and disease is a process of great
complexity that offers a number of mechanisms by which
cytomegalovirus infection of multiple cell types might serve as a
stimulatory cofactor in the development of more severe choroidal
neovascularization, we elected to focus our study on a possible role
for macrophages during chronic systemic MCMV infection.
Macrophages can be either pro-angiogenic or anti-angiogenic
depending on their polarization phenotype [25] that is regulated
by the cytokine patterns encountered by macrophages within the
resident tissue milieu [23,26]. Classically activated macrophages,
or M1 macrophages, exhibit an anti-angiogenic phenotype and
produce high amounts of IL-12, IL-23, IL-6, and TNF-a, but low
amounts of IL-10 [81]. In comparison, alternatively activated
macrophages, or M2 macrophages, exhibit a pro-angiogenic
phenotype and produce high amounts of IL-10, but low amounts
of pro-inflammatory cytokines such as IL-6 and TNF-a [81].
Moreover, M1 macrophages inhibit angiogenesis by inducing a
cell-death program in endothelial cells, whereas M2 macrophages
promote angiogenesis by stimulating production and release of
pro-angiogenic factors such as VEGF that encourage endothelial
tip cell formation [52]. In this regard, Fantin and coworkers [67]
have recently made the extraordinary observation that M2
macrophages may also play a critical role during formation of
new blood vessels by serving as bridge cells to properly position
and fuse neotubules into one continuous blood vessel, possibly via
activation of the DII4-a ligand and expression of Notch receptors
[82]. Thus, cytomegalovirus infection of monocytes and macro-
phages may influence angiogenesis-related activities by several
possible mechanisms. For example, HCMV infection of mono-
cytes appears to influence the polarization phenotype of the
activated macrophage by modulating in a selective manner many
M1/M2-associated factors [52,83], thereby inducing angiogenesis
through stimulation of VEGF production and other angiogenic
factors. Importantly, MCMV-infected IC-21 mouse macrophages
exhibited a pro-angiogenic M2 phenotype in our studies.
Alternatively, HCMV infection could conceivably have a
detrimental on the normal angiogenic process by promoting
inflammation. HCMV infection of endothelial cells may also
enhance the stability of newly formed blood vessels through
stimulation and release of several cytokines and growth factors
including the Notch 2 receptor [83]. We therefore postulate that
chronic MCMV infection results in more severe choroidal
neovascularization in our study by driving monocytes toward a
M2 macrophage phenotype that favors angiogenesis through
stimulation and release of pro-angiogenic factors that includes
VEGF. It has not escaped our attention, however, that chronic
MCMV infection might also cause more severe choroidal
neovascularization by direct or indirect mechanisms associated
with endothelial cell infection, a focus of future studies.
Splenic macrophages collected from chronically infected mice
with the most severe choroidal neovascularization in our study
showed significant increases in the amounts of transcripts to
MMP-9 and COX-2, two proteins known to be involved in
angiogenesis [52]. The most dramatic increase in transcript level,
however, was observed for that of VEGF, a critical pro-angiogenic
factor. This observation was confirmed in a second independent
animal study by us that demonstrated an even greater increase in
VEGF transcript production in splenic macrophages collected
from chronically infected animals. One interpretation of these
reproducible findings is that when chronically infected monocytes
are recruited to choroidal sites of laser-induced damage, their
activation programs are initiated and oriented toward the pro-
angiogenic M2 phenotype. Since they are also chronically infected
with MCMV, this activation program stimulates virus replication,
an event that leads to enhanced production and secretion of
several pro-angiogenic factors including VEGF. Inoculation of
cultures of human foreskin fibroblasts or cultures of coronary
artery smooth muscle cells with HCMV has been shown to result
in stimulation of functionally active VEGF production [78]. It is
therefore not surprising in the present study that MCMV infection
of cultures of IC-21 mouse macrophages significantly stimulated
production of VEGF mRNA and VEGF protein. Additional
observations made during immunostaining studies also demon-
strated that VEGF is indeed produced in high amounts by
MCMV-infected IC-21 mouse macrophages, especially those in
the early stages of cytopathology during plaque formation.
Of particular interest, however, was the additional observation
that monolayer cells too early to be infected with MCMV (given
the low multiplicity of infection used) were also VEGF-positive, an
observation suggesting the attractive hypothesis that uninfected
bystander macrophages might also be stimulated by adjacent
MCMV-infected macrophages to produce enhanced amounts of
VEGF during virus infection. Thus, MCMV infection of resident
macrophages of tissues of the lung and spleen, and even bone
marrow cells, could conceivably contribute to macrophage
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row cells, especially stromal cells, could favor a pro-angiogenic
microenvironment that induces bystander activation during
development within the marrow since stromal cells serve as a
substrate upon which monocytes are induced to differentiate [84].
In addition, due to their high vascularity, both lung and spleen
experience high monocyte traffic, and chronic MCMV infection of
these tissues could induce bystander activation. We therefore
postulate that chronic MCMV infection of monocytes and
macrophages distant from the eye serves as an important
mechanism for macrophage activation of the M2 phenotype that
would contribute to the pro-angiogenic microenvironment of the
choroidal tissues of the eye.
Treatment with ganciclovir, a potent inhibitor of active
cytomegalovirus replication and HCMV disease in the clinical
setting [42,43], has been shown to delay the time to development
of allograft rejection in heart transplant recipients [85,86], a
finding that underscores the importance for active HCMV
replication in acceleration of vascular disease. Additional studies
using experimental rat transplant models have provided similar
data showing that ganciclovir therapy also reduced or prevented
RCMV-associated acceleration of tissue rejection when compared
with RCMV-infected animals not treated with the antiviral
[87,88]. Since we hypothesize that MCMV infection of macro-
phages plays a central role in amplifying the severity of
experimental choroidal neovascularization in mice by stimulation
of pro-angiogenic factors including VEGF, we used a similar
antiviral approach to demonstrate that VEGF-specific transcript
production by splenic macrophages collected from chronically
infected mice was indeed ganciclovir-sensitive. This outcome
strongly supports the need for active MCMV virus replication in
stimulation of production of pro-angiogenic factors such as VEGF
that is required for increased severity of choroidal neovascular-
ization. These in vivo findings were duplicated and extended in
culture using ganciclovir-treated, MCMV-infected monolayers of
IC-21 mouse macrophages, and in a relatively dose-dependent
manner.
In summary, the findings reported herein using an experimental
mouse model of CNV serve to clarify our previous seroepidemi-
ologic clinical study in which a significant association was
identified between high titers of anti-HCMV IgG and develop-
ment of neovascular AMD [35]. The presence of high anti-
HCMV titers may indicate a subset of patients who harbor a
greater total body burden of chronic HCMV infection, or who
have experienced a recent, significant reactivation event. In either
case, we hypothesize that the blood load of circulating HCMV-
infected monocytes would be exceptionally high in this subset of
patients. Upon recruitment to sites of drusen formation in patients
who manifest the dry form of AMD, HCMV-infected monocytes
would mature into tissue-resident macrophages with active virus
replication, become polarized toward the pro-angiogenic M2
phenotype, and become a major source for production of a
number of pro-angiogenic factors including VEGF that would
amplify choroidal neovascularization associated with the wet form
of AMD. We therefore believe that HCMV infection should be
considered as a heretofore unrecognized risk factor for develop-
ment of neovascular AMD. If true, subsets of patients who harbor
a low virus load of HCMV would be predicted to experience
decreased onset and progression of choroidal neovascularization,
an occurrence that would impact their clinical outcome in terms of
time of onset of visual loss and degree of visual loss. It is therefore
possible that antiviral treatment might be effective in suppressing
choroidal neovascularization associated with wet AMD in a
fashion similar to that for suppression of allograft rejection in heart
transplant recipients. Future studies will be oriented toward this
investigation.
Materials and Methods
Ethics statement
All animal procedures were performed in strict accordance with
the Association for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vision
Research, and with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. Animal research protocols were approved by the
Institutional Animal Care and Use Committees of the University
of Miami Miller School of Medicine (A3324-01) and Georgia State
University (A3914-01). All laser treatments were performed under
anesthesia (intramuscular administration of ketamine hydrochlo-
ride, xylazine, and adepromazine), and all efforts were made to
minimize suffering.
Mice
Adult female C57BL/6 mice were purchased from the National
Institute of Aging (Bethesda, Maryland), and used throughout this
investigation. Mice were allowed unrestricted access to food and
water and maintained in alternating 12-hour light-dark cycles.
Virus
Stocks of MCMV were prepared in mouse salivary glands as
described previously [89]. Briefly, BALB/c mice (Taconic Farms,
Germantown, New York) were infected intraperitoneally with
1610
2 to 1610
3 plaque-forming units (PFU) of the Smith strain of
MCMV (American Type Culture Collection, Manassas, VA)
contained within a 0.2-ml volume. Approximately 14 days later,
the salivary glands were removed aseptically, homogenized (10%
wt/vol) in Dulbecco’s modified Eagle’s tissue culture medium
containing 10% fetal bovine serum (DMEM), clarified by
centrifugation, and 0.25 ml aliquots of the supernatant stored in
liquid N2. Virus stocks were titered on monolayers of mouse
embryo fibroblasts (MEF) grown in DMEM. Fresh aliquots of
MCMV stock were thawed and used for single experiments. UV-
inactivated virus was prepared by exposure of aliquots of MCMV
stock to ultraviolet radiation for 30 min to inactivate virus
infectivity as determined by no detectable plaque formation on
MEF monolayers 7 days after undiluted inoculation.
Experimental plans
Plan 1: To evaluate CNV severity after acute or chronic
infection with MCMV, four groups of mice (n=10 mice per
group) were injected intraperitoneally with 40 ul of a non-lethal
dose of infectious MCMV (1.5610
6 plaque-forming units) or with
an equivalent dose of UV-inactivated MCMV (controls). At 6 days
(acute infection) and at 6 weeks and 12 weeks (chronic infection)
after inoculation, the eyes of age-matched mice were subjected to
bilateral laser treatment to induce CNV as described below. Mice
were matched in age (10 months) at time of laser treatment. Four
weeks later, the right eyes were collected for flat-mount analysis,
and the left eyes were collected for histopathologic analysis.
Plan 2: To evaluate macrophages for their patterns of
production of various pro-angiogenic factors during CNV at time
of acute versus chronic MCMV infection, the eyes of groups of
mice (n=10 mice per group) were subjected to bilateral laser
treatment at 6 days or at 12 weeks after intraperitoneal injection
with infectious MCMV. The control group for this study consisted
of groups of mice injected intraperitoneally with UV-inactivated
virus. Mice were matched in age (10 months) at time of laser
MCMV and CNV Severity
PLoS Pathogens | www.plospathogens.org 12 April 2012 | Volume 8 | Issue 4 | e1002671treatment for these animal groups. Four weeks after CNV
induction, splenic macrophages were collected from all animals
for quantitative RT-PCR assay analysis of several gene transcripts
relevant to inflammation and/or neovascularization. Whole eyes,
choroidal tissues, tissues from various organs (salivary glands, lung,
spleen), and bone-marrow cells (CD34+ cells) were also collected
from mice of the same animal groups and analyzed by standard
plaque assay for detection of infectious virus or analyzed by PCR
assay for detection of MCMV-specific DNA sequences.
Plan 3: To confirm mouse macrophages as a source for VEGF
production following MCMV infection, monolayers of the IC-21
mouse macrophage cell line (American Type Culture Collection,
Manassas, VA, USA) [41] were inoculated either with MCMV
(moi=2.5), UV-inactivated MCMV, maintenance medium only,
or maintenance medium containing lipopolysaccharide (LPS)
(100 ng/ml). All cells were harvested at 24 or 48 hrs postinfection
and subjected to quantitative real time RT-PCR assay for
quantification of VEGF mRNA and TNF-a mRNA, standard
ELISA for quantification of VEGF protein production, or
immunostaining for detection and pattern of VEGF production.
Plan 4: To determine the effect of antiviral treatment on
production of VEGF mRNA and TNF-a mRNA by splenic
macrophages at time of chronic MCMV infection, groups of mice
(n=10 mice per group) were injected intraperitoneally with 40 ul
of a non-lethal dose of infectious MCMV (1.5610
6 plaque-
forming units) or maintenance medium (mock infected). At 12
weeks after inoculation, MCMV-infected or mock-infected mice
were treated intraperitoneally with ganciclovir for 7 days at a dose
of 40 mg/kg/day, a dose that reflects the relative decreased
sensitivity of MCMV to ganciclovir when compared with the
sensitivity of HCMV to ganciclovir [43]. Untreated control
MCMV-infected or mock-infected mice received daily intraperi-
toneal injections of phosphate-buffered saline for 7 days. Following
the 7-day regimen of ganciclovir or phosphate-buffered saline
treatment, splenic macrophages were collected from ganciclovir-
treated and untreated chronically infected mice and compared by
quantitiative real time RT-PCR assay for levels of VEGF mRNA
production. To determine the effect of antiviral treatment on
production of VEGF mRNA and TNF-a mRNA by mouse
macrophages during acute MCMV infection, monolayers of IC-21
mouse macrophages were inoculated either with MCMV
(moi=2.5) or mock-infected with maintenance medium. At 1-hr
postinfection, MCMV-infected and mock-infected monolayers
were treated either with 15, 30, or 60 uM of ganciclovir or
treated with phosphate-buffered saline (control). At 24 hr
postinfection, all monolayers were harvested and subjected to
quantitative RT-PCR assay for quantification and comparison of
levels of VEGF mRNA production.
Mouse model of laser-induced CNV and morphometric
analysis of severity
At 6 days, 6 weeks, or 12 weeks after injection with infectious or
UV-inactivated MCMV, diode red laser was used to create
choroidal thermal burns bilaterally and induce experimental CNV
as described previously [39]. Four weeks after laser application,
mice were euthanized, and subjected to histopathologic analysis as
well as flat-mount analysis of surface area, vascularity, and cell
density of CNV. All images were digitally acquired (Axiovision,
Zeiss) and recompiled (Photoshop version 6.0; Adobe, San Jose,
California). Surface area of CNV lesions was determined by using
either fluorescein-isothiocyanate (FITC)-dextran (Sigma, St. Louis,
Missouri) fluorescence or propidium iodide (PI, Sigma) fluores-
cence, and outlining the margins of the lesion with a computer
analysis software (Photoshop 6.0). The area in pixels was
normalized by dividing the average of the optic disc measured
in 10 independent eyes. Five eyes were examined 4 weeks after
laser treatment to determine the average spot size (0.48 disc areas).
A CNV was determined to be present if the surface area of an
individual lesion was greater than 0.50 disc areas.
Histopathologic analysis
Four weeks after bilateral laser treatment of groups of mice
infected systemically with MCMV for 6 days, 6 weeks, or 12
weeks, left eyes were carefully removed from all animals following
euthanasia, fixed in 10% buffered formalin, paraffin embedded,
sectioned with hematoxylin and eosin, and examined by light
microscopy for detection and quantification of areas of CNV.
Macrophage collection and enrichment
Following removal of spleens under sterile conditions from
euthanized mice, a Spectra/Mesh macroporus 210 mm filter
(Spectrum Laboratories, Inc., Los Angeles, California) was used to
obtain splenic macrophages after maceration of individual spleens
in a Hanks balance salt solution (HBSS) medium containing 1 M
HEPES, 1 M NaAZ, and fetal bovine serum. ACK buffer was
added to the spleen suspension to lyse red blood cells. The
remaining cells were centrifuged and resuspended in HBSS
medium containing rat anti-mouse F4/80 conjugated with PE
(Caltag, Burlingame, California). Splenic macrophages were then
purified by magnetic column separation using MACS Anti-PE
Microbeads (Miltenyi, Auburn, California) as specified by
manufacturer’s instructions.
Whole bone marrow cell collection and enrichment
At the time of euthanasia and under sterile conditions, tibias
and femurs were dissected and bone marrow was extracted by
slowly flushing the dyaphyseal channel with HBSS medium using
a 27-gauge needle. Bone marrow was homogenized, filtered,
centrifuged, and resuspended in HBBS medium. Red blood cells
were lysed with ACK buffer, and the remaining cells were
incubated with rat anti-mouse CD34 conjugated with PE (BD
Biosciences, Pharmingen, San Diego, California). CD34+ vascular
precursor cells were then purified by magnetic column separation
using MACS Anti-PE Microbeads (Miltenyi) as specified by
manufacturer’s instructions.
Detection of infectious MCMV
Whole eyes collected from mice at 30 days after laser-induced
CNV were frozen individually at 280uC. At time of quantitative
plaque assay, eyes were thawed, homogenized individually in
1.0 ml of cold Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum, and clarified by centrifuga-
tion. Ten-fold dilutions of the resulting supernatants were titered
in duplicate onto monolayers of MEF contained within 6-well
plates, allowed to absorb for 1 hour at 37uC, overlaid with
methylcellulose containing DMEM, and incubated for 5 or 6 days
at 37uC in a humidified CO2 atmosphere. Monolayers were
screened daily for 7 days using an inverted light microscope for
detection of plaques of MCMV-induced cytopathology.
PCR assay for MCMV-specific DNA
DNA was extracted from whole eyes, salivary glands, lungs,
bone marrow, spleens, and isolated macrophages collected from
euthanized mice using the QIAamp Tissue kit (QIAGEN GmbH,
Valencia, California) according to manufacturer’s instructions and
subjected to PCR assay to detect MCMV-specific DNA using
primers for immediate early 1 (IE1) and glycoprotein H (gH)
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Sedmak, Ohio State University College of Medicine, Columbus,
Ohio. The primer pair for MCMV IE1 gene was 59-TAGC-
CAATG ATATCTTCGAGCG-39 and 39-ATCTGGTGCTC-
CTCAGATCAGCTAA-59, and the primer pair for MCMV gH
gene was 59-TTCAGTTCAACTCGAA-39 and 39-GGGAA-
GAAGTACTCGACCGG-59. PCR amplification of b-actin was
performed as an internal control. Actin primers consisted of 59-
ATTGTGATGGACTCCGGTGA-39 and 39-AGCTCATAGC-
TCTTCTCCAG-59. DNA extracted from tissue homogenates
was eluted in 100 ml of distilled water, and stored at 220 C until
analysis. DNA was amplified in a total volume of 25 ml with
200 nM of each primer and 1.0 U of Taq DNA polymerase
(Gibco BRL) added in 2.5 ml of a PCR buffer (50 mM KCL,
20 mM Tris-HCl [pH 8.4], and 1.5 mM MgCl2). PCR assays
were performed on a Perkin Elmer 9600 thermocycler (PE
Applied Biosystems). PCR assay conditions consisted of an initial
denaturation step of 4 min at 94 C, followed by 35 cycles, with 1
cycle consisting of 30 sec at 94 C, 30 sec at 53 C, and 30 sec
72 C. Amplification products were separated by electrophoresis
through 1% agarose gels, and stained with ethidium bromide for
visualization.
Quantitative real-time RT-PCR assay
Total RNA was extracted from whole bone marrow cells
(CD34+ cells), splenic macrophages, or MCMV-infected IC-21
mouse macrophage monolayers using Tri-Reagent and prepared
for quantitative RT-PCR reactions as described previously [90].
Real time RT-PCR assay was used to quantify several cellular
transcripts of interest that included mouse tumor necrosis factor-
alpha (TNF-a), matrix metalloproteinase-9 (MMP-9), vascular
endothelial growth factor (VEGF), VEGF receptor 1 (VEGFR1),
VEGF receptor 2 (VEGFR2), platelet-derived growth factor-beta
(PDGF-b), cyclooxygenase (COX-2), and inducible nitric oxide
synthase (iNOS). Real time RT-PCR assays were performed for
TNF-a, VEGFR1, VEGFR2, and COX-2 mouse transcripts using
commercially available kits (Perkin Elmer Applied Biosciences).
The primer pair for real time RT-PCR assay of mouse PDGF-b
mRNA was 59-AAGCACACGCATGACAAG-39 and 39-GG-
GGCAATACAGCAAATAC-59; for VEGF mRNA was 59-
CGAAACCATGAACTTTCTGC-39 and 39-CCTCAGTGGG-
CACACACTCC-59; for MMP-9 mRNA was 59-CAGGA-
TAAACTGTATGGCTTCTGC-39 and 39- GCCGAGTTGCC-
CCCA-59; and for iNOS mRNA was 59-TGACGCCAAACAT-
GACTTCAG-39 and 39-GCCATCGGGCATCTGGTA. Tran-
scripts of these molecules were normalized to 18S ribosomal RNA
transcripts via standard curves generated using serially diluted
samples of mRNA (0.001–100 ng). Real time RT-PCR assays
were performed in duplicate with quantitative values determined
for each molecule as the ratio of the mean values for a specific
mRNA versus 18S mRNA. Median values for each molecule were
calculated and normalized to samples obtained from sham-
inoculated control animals (100%).
Immunostaining for detection of VEGF
MCMV-infected and mock-infected monolayers of IC-21
mouse macrophages grown on 6-well chamber slides were
harvested at 24 and 48 hr postinfection, fixed in cold ethanol,
dried, and reacted with 5% normal goat serum containing 0.2%
Triton X-100. Following three washings in phosphate-buffered
saline, slides were incubated for 1 hr with either rabbit anti-mouse
VEGF IgG (1:100 dilution) (Santa Cruz Biotechnology, Santa
Cruz, CA) or normal rabbit IgG (1:100 dilution (Santa Cruz
Biotechnology, Santa Cruz, CA), washed three times with
phosphate-buffered saline, and reacted with biotinylated anti-
rabbit IgG secondary antibody using the Rabbit ABC Staining
system (Santa Cruz Biotechnology, Santa Cruz, CA). Chamber
slides were mounted on standard microscope slides and cell nuclei
were counterstained using Vectashield Mounting Medium con-
taining DAPI (Vector Laboratories, Burlingame, CA). All slides
were examined and photographed using a Nikon Eclipse 50i
microscope equipped with an X-Cite Series 120 Epi-fl illuminator.
Statistical analysis
Morphometric data for individual lesions in each eye were
averaged to provide one value per eye. Mean and standard
deviation values for each group was calculated and p values were
determined using student t-test and one-way analysis of varian-
ce+Dunnett’s multiple comparison post-hoc test (GraphPad Prism
4.0, San Diego, CA). Values of p#0.05 were considered
statistically significant for all forms of statistical analysis used.
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